Distribution of total net revenues

MSEK

2017

2016

2017

2016

2016

 

Apr-Jun

Apr-Jun

Jan-Jun

Jan-Jun

Jan-Dec

Zubsolv® US

124.1

112.8

238.2

211.2

481.8

Zubsolv – Rest of the World

-

65.4

-

65.4

65.9

Zubsolv – total               

124.1

178.2

238.2

276.6

547.7

Abstral royalties

9.7

5.4

18.4

13.6

100.4

Milestone payment Abstral

-

-

-

-

2.2

Abstral – total

9.7

5.4

18.4

13.6

102.6

Edluar royalties

3.4

4.5

8.0

8.1

14.8

OX-CLI

21.8

-

21.8

40.8

40.8

Total

159.1

188.2

286.4

339.2

705.9

 

 Key figures

 

2017

2016

2017

2016

2016

 

Apr-Jun

Apr-Jun Restated

Jan-Jun

Jan-Jun Restated

Jan-Dec

 

 

 

 

 

 

EBIT margin, %

6.2

6.4

-4.7

-4.2

7.0

Return on shareholder equity, %

1.1

2.1

-10.8

-11.6

10.0

Net debt, MSEK

45.7

242.6

45.7

242.6

115.4

Debt/equity ratio, %

123.3

206.0

123.3

206.0

128.2

Equity/assets ratio, %

28.3

22.2

28.3

22.2

30.5

Number of shares, before dilution

34,539,585

34,583,763

34,539,585

34,583,763

34,477,423

Number of shares, after dilution

34,551,912

34,688,754

34,539,585

34,688,754

34,574,412

Earnings per share, before dilution, SEK

0.09

0.14

-0.91

-0.85

0.84

Earnings per share, after dilution, SEK

0.09

0.14

-0.91

-0.85

0.84

Number of employees at the end of the period

98

99

98

99

102

Shareholders’ equity, MSEK

275.8

240.5

275.7

240.5

310.3

Capital employed, MSEK

615.8

736.0

615.8

736.0

708.1

Working capital, MSEK

105.2

545.3

105.2

545.3

524.2

 Cash flow

 

Cash flow

SEK million

Q2

2017

Q2 2016

H1

2017

H1 2016

Jan - Dec

2016

Cash flow from operating activities

48.7

20.0

76.9

42.5

156.2

Investment activities

-0.5

-0.2

-0.8

10.8

5.4

Financing activities

-

-

-59.0

-

-90.6

Cash flow (excl exchange rate differences)

48.2

19.8

17.2

53.3

71.0

Liquid funds

294.3

252.9

294.3

252.9

282.4